ClinicalTrials.gov record
Recruiting Phase 1 Interventional

Gilteritinib for the Treatment of ALK NSCLC

ClinicalTrials.gov ID: NCT06225427

Public ClinicalTrials.gov record NCT06225427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT06225427
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Enrollment
30 participants

Conditions and interventions

Interventions

  • Biopsy Procedure
  • Biospecimen Collection Procedure
  • Computed Tomography Procedure
  • Echocardiography Procedure
  • Gilteritinib Drug
  • Magnetic Resonance Imaging Procedure
  • Questionnaire Administration Other

Procedure · Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 24, 2024
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027
Last update posted
Oct 19, 2025

2024 – 2027

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Cedars-Sinai Medical Center Los Angeles California 90048 Not yet recruiting
Georgetown University Washington D.C. District of Columbia 20007 Not yet recruiting
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06225427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06225427 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →